UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001961
Receipt number R000002303
Scientific Title Pre-operative chemotherapy with mFOLFOX6+Bevacizumab in liver only metastases from colorectal cancer -Phase II feasibility study-
Date of disclosure of the study information 2009/06/01
Last modified on 2009/05/12 22:40:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pre-operative chemotherapy with mFOLFOX6+Bevacizumab in liver only metastases from colorectal cancer
-Phase II feasibility study-

Acronym

FITS 0801

Scientific Title

Pre-operative chemotherapy with mFOLFOX6+Bevacizumab in liver only metastases from colorectal cancer
-Phase II feasibility study-

Scientific Title:Acronym

FITS 0801

Region

Japan


Condition

Condition

colorectal cancers

Classification by specialty

Gastroenterology Gastrointestinal surgery Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety of liver resection for metastatic lesions from colorectal cancers after neoadjuvant chemotherapy (mFOLFOX6+bevacizumab)

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Feasibility

Key secondary outcomes

R0(have tumor free margin) + R1(no tumor free margin)rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Surgery

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1,2) Histologically or cytologically confirmed colorectal cancer confined to the liver
3) No extrahepatic metastases (If present, primary tumor must be potentially resectable with curative intent)
4) Measurable disease
5) Resectable or unresectable disease
6) No prior chemotherapy or radiotherapy (Prior adjuvant chemotherapy for primary cancer is allowed provided it is other than FOLFOX and at least 24 weeks have passed since last treatment)
7) No prior locoregional therapy for liver metastases
8) Age 20 to 75 years old
9) ECOG performance status 0-1
10) Life expectancy of &>13 weeks at the time of enrollment
11) Adequate organ functions as follows:
WBC 4,000-12,000/mm3
ANC>2,000/mm3
Platelet count>100,000 /mm3
Hemoglobin>9 g/dL
AST or ALT< 3 times ULN
Bilirubin<1.5 times ULN
Creatinine<1.5 times ULN
12) Written informed consent.

Key exclusion criteria

1) Active or previous history of interstitial pneumonia or pulmonary fibrosis confirmed by chest X-ray
2) Fluid retention requiring treatment
3) Other active malignancies unless the patient has been disease-free and received no treatment for the malignancy for &<5 years prior to study entry.
4) Peripheral neuropathy
5) Active infectious diseases
6) Ileus, Diarrhea
7) Diabetes mellitus, uncontrolled or controlled with chronic insulin therapy
8) Gastrointestinal perforation either concurrently or within 1 year prior to study entry
9) Previous history of ischemic heart disease
10,13) Psychiatric or medical condition that would preclude study compliance
11) Positive for HIV antibody and/or HBs antigen and/or HCV antibody
12) Concurrent chronic steroid therapy
14) Concurrent antithrombotic therapy
15) Chronic therapy with platelet function inhibitor
16) Evidence of bleeding diathesis or coagulopathy
17) Uncontrolled hypertension
18) Pregnant or lactating women, or fertile women of childbearing potential not using adequate contraception
19) Previous history of severe drug hypersensitivity
20) Any other conditions that would preclude study compliance

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tetuso Ota

Organization

Kanazawa University Hospital

Division name

Surgery

Zip code


Address

13-1 Takara-machi, Kanazawa city

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Hideto Fujita

Organization

Kanazawa University Hospital

Division name

Surgery

Zip code


Address


TEL


Homepage URL


Email

hfujita@mail.kanazawa-u.ac.jp


Sponsor or person

Institute

Dept.Surgery
Kanazawa University Hospital

Institute

Department

Personal name



Funding Source

Organization

Dept.Surgery
Kanazawa University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2008 Year 10 Month 22 Day

Date of IRB


Anticipated trial start date

2008 Year 12 Month 01 Day

Last follow-up date

2010 Year 11 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 05 Month 12 Day

Last modified on

2009 Year 05 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002303


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name